Every 8-K that Nkarta, Inc. (NKTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow NKTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NKTX filings page.
Nkarta, Inc. reported second quarter 2026 results while advancing its NKX019 autoimmune program. Enrollment is ongoing across all indications in the Ntrust-1 and Ntrust-2 dose-escalation trials at a regimen of 4 billion cells per dose across three doses, and outpatient dosing has begun at community-based sites with potential re-dosing.
As of June 30, 2026, Nkarta held $243.2 million in cash, cash equivalents, restricted cash and investments, and expects this to fund its current operating plan into 2029. For the quarter, research and development expenses were $29.0 million and general and administrative expenses were $14.1 million, both higher than the prior-year period. Net loss was $40.4 million, or $0.54 per share, including $11.8 million of non-cash charges such as $8.0 million of impairments, $2.7 million of depreciation and $1.9 million of share-based compensation.
Nkarta, Inc. held its 2026 annual meeting of stockholders on June 10, 2026. Stockholders elected Class III directors Ali Behbahani and Zachary Scheiner to terms running until the 2029 annual meeting. They also ratified Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026.
Stockholders approved, on a non-binding advisory basis, the compensation paid to the company’s named executive officers and voted on how often to hold future say-on-pay votes. Based on the vote, the company will hold advisory executive compensation votes every year until the next required frequency vote.
Nkarta, Inc. reported first quarter 2026 results and progress in its NKX019 autoimmune program. The company ended March 31, 2026 with $266.7 million in cash, cash equivalents, restricted cash and marketable securities, and expects this balance to fund its current operating plan into 2029.
For the quarter, research and development expenses were $25.0 million and general and administrative expenses were $5.9 million, with both including non-cash stock-based compensation. Nkarta recorded a net loss of $27.8 million, or $0.37 per share, narrower than the loss in the prior-year period, helped by lower operating expenses and interest income.
Clinically, enrollment continues in the Ntrust-1 and Ntrust-2 trials of NKX019 across multiple autoimmune diseases, with patients receiving a three-dose cycle totaling 12 billion cells. A recent FDA protocol amendment allows outpatient dosing in community settings, re-dosing options, and expansion of Ntrust-2 to include rheumatoid arthritis, with initial clinical data planned for presentation in 2026.
Nkarta, Inc. entered into a Sales Agreement with Stifel, Nicolaus & Company for an at-the-market stock offering program. The company may sell, at its discretion, shares of common stock having an aggregate offering price of up to $100,000,000 through Stifel as sales agent.
The company will set sale parameters such as size, timing, daily limits and minimum prices, and will pay Stifel a commission of up to 3% of gross proceeds on shares sold. The shares will be issued under Nkarta’s effective Form S-3 registration statement and related at-the-market prospectus supplement filed with the SEC on March 25, 2026.
Nkarta, Inc. reported fourth quarter and full year 2025 results and highlighted progress in its NKX019 autoimmune program. Cash, cash equivalents, restricted cash and investments totaled $295.1 million as of December 31, 2025, and are expected to fund operations into 2029.
For 2025, Nkarta recorded a net loss of $104.1 million, or $1.41 per share$90.4 million and general and administrative expenses were $31.6 million. Fourth quarter 2025 net loss was $27.4 million, or $0.37 per share.
Clinically, dose escalation for NKX019 advanced to 4 billion cells per dose on days 0, 3 and 7, for a total of 12 billion cells per cycle in the Ntrust-1 and Ntrust-2 autoimmune trials. Initial clinical data from these trials are planned for presentation at a medical conference in 2026.
Nkarta, Inc. furnished an update on its business by announcing that it issued a press release with financial results for the third quarter ended September 30, 2025. The company provided this update via a current report and attached the press release as Exhibit 99.1 titled “Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights.”
The disclosure states that the information, including Exhibit 99.1, is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act.
Nkarta, Inc. furnished a press release announcing its financial results for the second quarter ended June 30, 2025, and attached that press release as Exhibit 99.1 to this Current Report on Form 8-K. The Form 8-K also includes a Cover Page Interactive Data File as Exhibit 104. The filing states the Item 2.02 disclosure (including Exhibit 99.1) is being furnished and shall not be deemed "filed" under the Exchange Act nor incorporated by reference into filings under the Securities Act or the Exchange Act unless the company expressly states otherwise.
The filing identifies the registrant as a Delaware corporation (Commission File Number 001-39370; EIN 47-4515206), lists its principal executive office in South San Francisco, California, and shows the company’s common stock trades as NKTX on the Nasdaq Global Select Market. The report is signed by Nadir Mahmood as President.